Skip to main content
. 2015 Aug 12;1(1):e000037. doi: 10.1136/rmdopen-2014-000037

Figure 1.

Figure 1

Patient disposition. Eligibility was assessed during screening, then randomisation to 24 weeks of treatment (or 16 weeks for non-responders) in 1 of 2 tabalumab regimens or placebo and 48 weeks of follow-up. 120/Q4W=120 mg subcutaneous (SQ) tabalumab injection every 4 weeks; 90/Q2W=90 mg SQ tabalumab injection every 2 weeks.